For semaglutide, the relevant secondary patents include: Formulation patents covering the specific inactive ingredients, pH buffers, and stabilizers that keep semaglutide stable in solution (US 9,714,283, expires 2033) Method-of-use patents covering specific dosing schedules and titration protocols (US 10,195,214, expires 2032) Delivery device patents for the pen injector mechanism used in Ozempic and Wegovy (separate patent family, expires 2029-2031) Oral formulation patents for the SNAC (salcaprozate sodium) absorption enhancer used in Rybelsus tablets (US 9,931,349, expires 2032) The expiration date that matters to you depends on which formulation you care about
MDRN Myers $165 A Modern spin on the Myers IV cocktail
Final Thoughts What is AOD 9604
Success with Wegovy requires a long-term commitment to healthy habits and regular check-ups
Can TB500 Help With Tendonitis or Tendinosis